Top Medical News

Dabrafenib/Trametinib Elicits Viable Phase 2 Responses in BRAF V600E–Mutated Glioma

May 22nd 2022

Investigators reported that 33% of patients receiving dabrafenib plus trametinib for BRAF V600E–mutated glioma responded to treatment, including 3 complete responses and 12 partial responses.

Medication Extension Set Makes Subcutaneous Hyaluronidase Injections Easier, More Comfortable in Cancer Treatment

May 21st 2022

A medication extension set may be the preferred method for subcutaneous hyaluronidase injections compared with a traditional needle.

Heavily Pretreated Patients With Relapsed/Refractory Myeloma Achieve Encouraging Responses With Teclistamab Plus Daratumumab

May 20th 2022

An expert with the phase 1b TRIMM-2 trial underscores the significance and findings for patients with multiple myeloma.

Oncology Nurses Play Pivotal Role in Survivor Follow-Up Care

May 20th 2022

Michelle Mollica, PhD, MPH, RN, OCN, senior advisor in the NCI Office of Cancer Survivorship, discusses different long-term care considerations for nurses caring for patients with cancer.

Niraparib, Abiraterone, and Prednisone Triplet Shows Efficacy, Safety in mCRPC With HRR Gene Alterations

May 19th 2022

The combination of PARP inhibition and androgen receptor targeted therapy was found to be tolerable in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.


Most Recent